Abiraterone Toxicity Profile in mCRPC
Abiraterone does NOT cause significant pulmonary toxicity, but cardiac toxicity manifests primarily as hypertension, atrial fibrillation, cardiac failure, and arrhythmias related to mineralocorticoid excess. 1
Pulmonary Toxicity
Pulmonary toxicity with abiraterone is extremely rare. The FDA label identifies only non-infectious pneumonitis as a postmarketing adverse event, meaning it occurs so infrequently that it wasn't captured in the pivotal trials 1. In clinical trials, dyspnea occurred in 12% of patients (2.4% grade 3-4), but this was primarily related to disease progression or cardiac causes rather than direct lung toxicity 1.
Bottom line: Do not expect clinically meaningful pulmonary toxicity with abiraterone.
Cardiac Toxicity: The Real Concern
Cardiac toxicity is the critical safety issue with abiraterone and stems from mineralocorticoid excess due to CYP17 inhibition. This leads to accumulation of mineralocorticoid precursors upstream of the enzymatic block 2, 1.
Specific Types of Cardiac Toxicity:
1. Hypertension (Most Common)
- Occurs in 22% of patients (3.9% grade 3-4) 1
- Severe hypertension or cardiac disorders noted in 10% of patients 2
- Significantly higher risk than enzalutamide (HR 1.12 for MACE) 3
- Monitor blood pressure at least monthly 1
2. Cardiac Failure
- Occurs in 2.6% of patients overall (1.3% grade 3-4) 1
- Led to 5 treatment discontinuations and 4 deaths in combined trial data 1
- NT-proBNP and troponin T levels predict cardiac events: elevated levels at baseline and 3 months strongly associated with subsequent cardiac SAEs (P=0.03 and P=0.04 respectively) 4
3. Atrial Fibrillation
- Rare but significantly increased versus placebo 2
- 1.73-fold higher risk compared to enzalutamide (HR 1.73,95% CI 1.31-2.29, P<0.001) 3
4. Arrhythmias and Sudden Cardiac Events
- QT prolongation and Torsades de Pointes reported, especially with hypokalemia or underlying cardiovascular disease 1
- 7 deaths (0.3%) due to cardiorespiratory arrest in abiraterone arms versus 2 (0.1%) in placebo 1
- 3 deaths from myocardial ischemia/infarction 1
5. Ischemic Heart Disease
- Includes unstable angina requiring revascularization
- Higher risk versus enzalutamide (HR 1.13, P=0.041) 3
Metabolic Abnormalities Driving Cardiac Toxicity:
- Hypokalemia: 28% all grades (5.3% grade 3-4) 1
- Fluid retention/edema: 25% of patients 1
- Hypernatremia: 33% of patients 1
These mineralocorticoid effects are partially but incompletely suppressed by the concurrent prednisone 5 mg twice daily 2, 5.
Critical Monitoring Algorithm
Before starting abiraterone:
- Control pre-existing hypertension
- Correct hypokalemia
- Obtain baseline NT-proBNP and troponin T if cardiovascular disease history 4
During treatment (at least monthly):
- Blood pressure
- Serum potassium
- Liver function tests (ALT/AST)
- Consider NT-proBNP and troponin T at 1 and 3 months if cardiac risk factors 4
Red flags requiring dose hold or discontinuation:
- Grade 3-4 hypertension uncontrolled with medication
- Symptomatic cardiac failure
- Severe hypokalemia (<3.0 mEq/L)
- Grade 3-4 hepatotoxicity 1
Key Clinical Pitfalls
Patients ≥70 years have significantly worse outcomes: higher grade 3-5 adverse events (47% vs 33%), more treatment-related deaths (9 vs 3), and less survival benefit (HR 0.94 vs 0.51 in younger patients) 2. Exercise particular caution in elderly patients with pre-existing cardiovascular disease.
Prior cardiovascular disease amplifies risk: The increased MACE risk with abiraterone versus enzalutamide was confined to patients with CVD history in sensitivity analyses 3. Consider enzalutamide as first-line ARPI in patients with significant cardiac comorbidities.
Switching steroids may help: One small study showed no additional cardiac SAEs after switching from prednisone to dexamethasone plus canrenone (mineralocorticoid receptor antagonist) 4, though this requires validation.